Aardvark Therapeutics, Inc.
corporate_fare Company Profile
Aardvark Therapeutics, Inc. (NASDAQ:AARD) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for AARD at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for AARD spans 8-K, 10-Q, PRE 14A, 424B5.
Recent high-impact activity:
- Aardvark Books Q1 2027 FDA Meeting to Map ARD-101 Restart After Hold Lifted
- Q3 Loss Widens to 88 Cents a Share, Missing Consensus by 16 Cents
- Aardvark Q3 Loss Widens to $19.2M; Cash Down to $60.3M With Runway Into 2027
- Aardvark Posts Exploratory HERO/OLE Data, Targets New Phase 3 After FDA Hold Lift
- FDA Lifts Clinical Hold on ARD-101, Reviving PWS Program
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 1,038,938 shares in AARD as of the October 30, 2026 settlement, a 87.8% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 73.0% of AARD volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.